Publications by Professor David Kavanagh - ePrints

Browsing publications by Professor David Kavanagh.

Newcastle Authors	Title	Year
Professor David Kavanagh	An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group	2024
Anneliza Andreadi Dr Vicky Brocklebank Professor Kevin Marchbank Professor Claire Harris Professor David Kavanagh et al.	Comprehensive functional characterization of complement factor I rare variant genotypes identified in the SCOPE geographic atrophy cohort	2024
Dr Sally Johnson Professor David Kavanagh Professor John Sayer Dr Edwin Wong Megan Bates et al.	Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort	2024
Dr Sally Johnson Professor David Kavanagh Professor John Sayer Dr Edwin Wong Dr Vicky Brocklebank et al.	Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort	2024
Emily Glover Professor David Kavanagh Professor Neil Sheerin	Kidney Transplantation in Patients with aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy	2024
Professor David Kavanagh Dr Vicky Brocklebank Professor Neil Sheerin	Outcomes from the International Society of Nephrology Haemolytic Uraemic Syndromes International Forum	2024
Professor David Kavanagh	Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of Two-Year Efficacy and Safety Outcomes in Two Phase 3 Trials	2024
Dr Edwin Wong Lee-Ann Naidoo Sarah Winn Dr Patrick Walsh Dr Vicky Brocklebank et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2022/23	2024
Emily Glover Dr Kate Smith-Jackson Dr Vicky Brocklebank Dr Valerie Wilson Dr Patrick Walsh et al.	Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome	2023
Dr Vicky Brocklebank Dr Patrick Walsh Dr Kate Smith-Jackson Dr Thomas Hallam Professor Kevin Marchbank et al.	Atypical haemolytic uraemic syndrome in the era of terminal complement inhibition- An observational cohort study	2023
Dr Thomas Hallam Anneliza Andreadi Professor David Kavanagh	Complement Factor I: regulatory nexus, driver of immunopathology, and therapeutic	2023
Professor David Kavanagh	Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome	2023
Professor Kevin Marchbank Professor David Kavanagh Professor Claire Harris	Editorial	2023
Dr Edwin Wong Professor David Kavanagh	Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy	2023
Professor David Kavanagh	Iptacopan in Idiopathic Immune Complex–Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study	2023
Dr Edwin Wong Sarah Winn Dr Michal Malina Dr Sally Johnson Professor Neil Sheerin et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2021/22	2023
Dr Thomas Hallam Tom Cox Dr Kate Smith-Jackson Dr Vicky Brocklebank April Baral et al.	A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative CFI variants in Age-related Macular Degeneration	2022
Professor David Kavanagh	Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial	2022
Professor David Kavanagh	Complement and the prothrombotic state	2022
Dr Gemma Thompson Professor David Kavanagh	Diagnosis and treatment of thrombotic microangiopathy	2022
Professor Claire Harris Professor David Kavanagh	Evaluating a causal relationship between Complement Factor I protein level and advanced age-related macular degeneration using Mendelian Randomisation	2022
Dr Patrick Walsh Professor David Kavanagh	None Fits All: Unraveling Structural Rearrangements of the CFH Gene Cluster in Atypical Hemolytic Uremic Syndrome Patients Using Molecular Combing and Long-Fragment Targeted Sequencing	2022
Nik Tzoumas Professor David Kavanagh Professor Heather Cordell Professor David Steel	Rare complement factor I variants associated with reduced macular thickness and age-related macular degeneration in the UK Biobank	2022
Sarah Dunn Abishek Umashankar Andrew Bryant Dr Sonya Carnell Dr Thomas Chadwick et al.	Saftey and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study	2022
Professor David Kavanagh	Use of a B-cell depleting regimen for antifactor H autoantibody-mediated membranoproliferative glomerulonephritis in a paediatric patient	2022
Professor Kevin Marchbank Dr Isabel Pappworth Harriet Denton Kate Cooke Grant Richardson et al.	C3 Glomerulopathy and Related Disorders in Children.	2021
Dr Edwin Wong Thomas Hallam Dr Vicky Brocklebank Dr Patrick Walsh Dr Kate Smith-Jackson et al.	Functional characterisation of rare genetic variants in the N-terminus of complement factor H in aHUS, C3G and AMD	2021
Dr Ola Kamala Dr Thomas Hallam Tom Cox Dr Yi Yang Dr Falguni Vyas et al.	Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice	2021
Professor David Kavanagh	Interventions for atypical haemolytic uraemic syndrome.	2021
Professor David Kavanagh	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults	2021
Professor David Steel Professor David Kavanagh	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy	2021
Nik Tzoumas Dr Dean Hallam Professor Claire Harris Professor Majlinda Lako Professor David Kavanagh et al.	Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants.	2021
Dr Edwin Wong Sarah Winn Dr Michal Malina Dr Sally Johnson Professor Neil Sheerin et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2020/21	2021
Tom Hallam Gladys - Nik Tzoumas David Steel Victoria Shuttleworth et al.	The Rare C9 P167S Risk Variant for Age-related Macular Degeneration Increases Polymerization of the Terminal Component of the Complement Cascade	2021
Professor David Kavanagh	Cocaine-associated atypical haemolytic uraemic syndrome in a genetically susceptible individual	2020
Dr Tom Altmann Dr Stephen Owens Dr Dipayan Mitra Professor Neil Sheerin Professor David Kavanagh et al.	Complement Factor I deficiency: a potentially treatable cause of fulminant cerebral inflammation	2020
Edvinas Cerniauskas Dr Marzena Kurzawa-Akanbi Dr Long Xie Dr Dean Hallam Marina Moya Molina et al.	Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function	2020
Professor David Kavanagh	Functional Analysis of Rare Genetic Variants in Complement Factor I (CFI) using a Serum-Based Assay in Advanced Age-related Macular Degeneration	2020
Dr Vicky Brocklebank Dr Kate Smith-Jackson Dr Patrick Walsh Professor Kevin Marchbank Professor Claire Harris et al.	Long-term outcomes and response to treatment in DGKE nephropathy	2020
Professor David Kavanagh	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international multidisciplinary working group.	2020
Dr Zohreh Nademi Dr Alex Battersby Dr Terence Flood Dr Stephen Owens Professor Andrew Cant et al.	New Insights Into Risk Factors for Transplant-Associated Thrombotic Microangiopathy in Pediatric HSCT	2020
Dr Sanj Ugrinovic Professor David Kavanagh	Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency	2020
Tom Hallam Professor Kevin Marchbank Professor Claire Harris Victoria Shuttleworth Professor David Kavanagh et al.	Rare Genetic Variants in Complement Factor I Lead to Low FI Plasma Levels Resulting in Increased Risk of Age-Related Macular Degeneration	2020
Dr Edwin Wong Lisa Batchelor Dr Michal Malina Dr Sally Johnson Professor Neil Sheerin et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2019/20	2020
Professor David Kavanagh	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment	2020
Dr Veronique Fremaux-Bacchi Professor David Kavanagh	C3 glomerulopathy — understanding a rare complement-driven renal disease	2019
Dr Kate Smith-Jackson Dr Yi Yang Harriet Denton Katie Cooke Professor David Kavanagh et al.	Hyper-functional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice	2019
Dr Christopher Duncan Dr Benjamin Thompson Dr Rui Chen Dr Florian Gothe Victoria Shuttleworth et al.	Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2	2019
Dr Edwin Wong Jo Stout Jalibani Ndebele Angela Watt Lisa Batchelor et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2018/19	2019
Dr Patrick Walsh Professor David Kavanagh	Complement receptor CD46 co-stimulates optimal human CD8⁺ T cell effector function via fatty acid metabolism	2018
Professor Claire Harris Professor David Kavanagh Dr Ruyue Sun	Developments in anti-complement therapy; from disease to clinical trial	2018
Dr Edwin Wong Professor David Kavanagh	Diseases of complement dysregulation—an overview	2018
Dr Patrick Walsh Dr Sally Johnson Dr Vicky Brocklebank Dr Jacobo Salvatore Professor David Kavanagh et al.	Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome	2018
Professor David Kavanagh	Introduction to complement in health and disease: novel aspects and insights.	2018
Professor David Kavanagh Dr Valerie Wilson Professor Tim Goodship	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy	2018
Dr Edwin Wong Jo Stout Jalibani Ndebele Angela Watt Dr Michal Malina et al.	The Annual Report of the National Renal Complement Therapeutics Centre 2017/18	2018
Dr Vicky Brocklebank Dr Katrina Wood Professor David Kavanagh	Thrombotic microangiopathy and the kidney	2018
Dr Dean Hallam Dr Joseph Collin Dr Sanja Bojic Dr Valeria Chichagova Dr Adriana Buskin et al.	An iPSC patient specific model of CFH (Y402H) polymorphism displays characteristic features of AMD and indicates a beneficial role for UV light exposure	2017
Dr Vicky Brocklebank Professor David Kavanagh	Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea	2017
Dr Edwin Wong Dr Yi Yang Professor Kevin Marchbank Professor David Kavanagh	Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self surface-selective regulation of complement activation	2017
Dr Vicky Brocklebank Dr Sally Johnson Dr Patrick Walsh Dr Edwin Wong Dr Larissa Kerecuk et al.	Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland	2017
Professor David Kavanagh	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation	2017
Professor David Kavanagh Dr Edwin Wong Dr Vicky Brocklebank	Hemolytic Uremic Syndrome in Pregnancy and Post-Partum	2017
Dr Katrina Wood Dr Alison Brown Professor David Kavanagh Dr Vicky Brocklebank	Rare genetic variants in Shiga toxin–associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential	2017
Dr Edwin Wong Dr Sally Johnson Professor Neil Sheerin Professor David Kavanagh	The Annual Report of the National Renal Complement Therapeutics Centre 2016/2017	2017
Rachel Challis Dr Edwin Wong Dr Vicky Brocklebank Dr Valerie Wilson Professor Kevin Marchbank et al.	Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease	2017
Rachel Challis Dr Edwin Wong Dr Holly Anderson Dr Valerie Wilson Dr Vicky Brocklebank et al.	A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H–Related 3 Gene in Atypical Hemolytic Uremic Syndrome	2016
Professor Neil Sheerin Professor David Kavanagh Professor Tim Goodship Dr Sally Johnson	A national specialised service in England for atypical haemolytic uraemic syndrome – the first year’s experience	2016
Dr Valerie Wilson Tom Cox Dr Kate Smith-Jackson Professor David Kavanagh Professor Tim Goodship et al.	Chromosomal rearrangement – a rare cause of complement factor I associated atypical haemolytic uraemic syndrome	2016
Professor David Kavanagh Dr Kate Smith-Jackson	Eculizumab in children with hemolytic uremic syndrome	2016
Professor David Kavanagh	Role of factor H and effects of C-terminal mutations on control of human platelet/granulocyte aggregate formation	2016
Dr Vicky Brocklebank Dr Edwin Wong Professor Kevin Marchbank Professor Tim Goodship Professor David Kavanagh et al.	The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies	2016
Professor David Kavanagh Rachel Challis	Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature	2016
Dr Edwin Wong Professor David Kavanagh	Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome	2015
Dr Veronique Fremaux-Bacchi Professor Tim Goodship Professor David Kavanagh	Atypical aHUS: State of the art	2015
Rachael Horbury Dr Karim Bennaceur Catriona Barker Professor David Kavanagh Professor Tim Goodship et al.	Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS)	2015
Dr Edwin Wong Dr Vicky Brocklebank Professor Tim Goodship Professor David Kavanagh Dr Anna Richards et al.	Characterisation of a C3 Mutation with Increased Resistance to Complement Regulation in an Individual with Recurrent C3GN in a Renel Transplant	2015
Dr Edwin Wong Rachel Challis Professor Neil Sheerin Dr Sally Johnson Professor David Kavanagh et al.	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS)	2015
Dr Mustafa Sevinc Dr Vicky Brocklebank Professor Tim Goodship Professor David Kavanagh	Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report	2015
Professor David Kavanagh	Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels	2015
Professor David Kavanagh	Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum Factor I level	2015
Professor David Kavanagh	Structural basis for sialic acid-mediated self-recognition by complement factor H	2015
Professor David Kavanagh	Successful Treatment of Atypical Hus with Eculizumab in Emirati Child with Novel DGKE Gene Mutation	2015
Dr Vicky Brocklebank Dr Edwin Wong Professor Tim Goodship Professor David Kavanagh	Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri	2014
Catriona Barker Professor David Kavanagh Professor Tim Goodship Dr Isabel Pappworth	Autoantibodies to CD59, CD55, CD46 and CD35 are not associated with aHUS	2014
Dr Edwin Wong Dr Holly Anderson Rachel Challis Dr Lisa Turnbull Gladys - et al.	Characterization of a Factor H Mutation That Perturbs the Alternative Pathway of Complement in a Family with Membranoproliferative GN	2014
Professor David Kavanagh Professor Neil Sheerin	Management of hemolytic uremic syndrome	2014
Dr Vicky Brocklebank Professor David Kavanagh	Protecting the kidney from complement: atypical haemolytic uraemic syndrome	2014
Professor David Kavanagh	Thrombotic Microangiopathy Associated with Interferon Beta	2014
Dr Edwin Wong Professor David Kavanagh	Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration	2014
Rachel Challis Dr Holly Anderson Dr Edwin Wong Dr Lisa Turnbull Professor Kevin Marchbank et al.	Atypical haemolytic uraemic syndrome associated with a novel hybrid CFH/CFHR3 gene	2013
Professor David Kavanagh Professor Tim Goodship Dr Anna Richards	Atypical hemolytic uremic syndrome	2013
Dr Edwin Wong Professor Tim Goodship Professor David Kavanagh	Complement therapy in atypical haemolytic uraemic syndrome (aHUS)	2013
Dr Lucy Holmes Dr Lisa Turnbull Dr Iain Moore Professor Kevin Marchbank Professor David Kavanagh et al.	Determining the Population Frequency of the CFHR3/CFHR1 Deletion at 1q32	2013
Dr Holly Anderson Professor David Kavanagh	Rare variants in CFI, C3 and C9 are associated with high risk of advancedage-related macular degeneration.	2013
Professor David Kavanagh Dr Lisa Turnbull Professor Kevin Marchbank Professor Claire Harris Professor Tim Goodship et al.	A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome	2012
Professor Tim Goodship Dr Isabel Pappworth Dr Iain Moore Dr Eva-Maria Hunze James Staniforth et al.	Factor H autoantibodies in membranoproliferative glomerulonephritis	2012
Professor David Kavanagh Dr Isabel Pappworth Christine Hayes Dr Iain Moore Dr Eva-Maria Hunze et al.	Factor I Autoantibodies in Patients with Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon?	2012
Dr Edwin Wong Dr Holly Anderson Rachel Challis Professor Kevin Marchbank Professor David Kavanagh et al.	Familial membranoproliferative glomerulonephritis type I associated with a functionally significant mutation in complement factor H	2012
Professor David Kavanagh Marie Appleton Professor Kim Bartlett	Interference of urinary amino acid analysis by pregabalin	2012
Professor David Kavanagh Dr Holly Anderson	Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome	2012
Professor David Kavanagh	Structural and Functional Characterization of the Product of Disease-Related Factor H Gene Conversion	2012
Professor David Kavanagh	Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H	2011
Professor David Kavanagh Professor Claire Harris	Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities	2011
Professor David Kavanagh Professor Tim Goodship	Haemolytic Uraemic Syndrome	2011
Professor David Kavanagh Professor Tim Goodship Dr Veronique Fremaux-Bacchi	Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort	2011
Professor David Kavanagh	Structural basis for engagement by complement factor H of C3b on a self surface	2011
Professor David Kavanagh Dr Lisa Turnbull Professor Kevin Marchbank Professor Tim Goodship	A novel hybrid complement gene associated with familial haemolytic uraemic syndrome	2010
Dr Iain Moore Dr Lisa Turnbull Dr Isabel Pappworth Professor David Kavanagh James Staniforth et al.	Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome	2010
Professor David Kavanagh Professor Tim Goodship	Atypical hemolytic uremic syndrome	2010
Dr Isabel Pappworth Dr Iain Moore Dr Lisa Turnbull Professor David Kavanagh James Staniforth et al.	Complement Factor H Autoantibodies and Age-Related Macular Degeneration	2010
Dr Isabel Pappworth Professor David Kavanagh Dr Iain Moore Dr Lisa Turnbull	Factor H autoantibodies are associated with MPGN	2010
Professor David Kavanagh Dr Isabel Pappworth Dr John Tapson Dr Iain Moore Dr Lisa Turnbull et al.	Factor I autoantibodies are associated with atypical haemolytic uraemic syndrome	2010
Professor David Kavanagh Dr Lisa Turnbull Professor Kevin Marchbank Professor Tim Goodship	Functional characterisation of a novel hybrid complement factor H protein associated with atypical haemolytic uraemic	2010
Professor David Kavanagh Professor Tim Goodship	Genetics and complement in atypical HUS	2010
Professor David Kavanagh Professor Tim Goodship Dr Veronique Fremaux-Bacchi	Mutations in complement regulatory proteins predispose to preeclampsia	2010
Professor Tim Goodship Professor David Kavanagh	Pulling the Trigger in Atypical Hemolytic Uremic Syndrome: The Role of Pregnancy	2010
Professor David Kavanagh Professor Tim Goodship	Transplantation in Atypical Hemolytic Uremic Syndrome	2010
Professor Kevin Marchbank Professor David Kavanagh Dr Lisa Turnbull Professor Tim Goodship	Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1)	2010
Professor Kevin Marchbank Dr Lisa Turnbull Dr Veronique Fremaux-Bacchi James Staniforth Professor David Kavanagh et al.	Genomic disorders associated with aHUS	2009
Dr Anna Richards Professor David Kavanagh	Pathogenesis of thrombotic microangiopathy: insights from animal models	2009
Professor David Kavanagh	The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome	2009
James Staniforth Professor David Kavanagh Dr Lisa Turnbull Professor Tim Goodship Professor Kevin Marchbank et al.	Towards a highly specific Factor H ELISA for rapid screening of patient sera	2009
Professor David Kavanagh	A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H	2008
Dr Matthew Edey Professor David Kavanagh Dr Anne Lampe Professor Judith Goodship Dr Lisa Turnbull et al.	A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity	2008
Professor David Kavanagh	Advances in understanding of pathogenesis of aHUS and HELLP	2008
Professor David Kavanagh Dr Anna Richards	Complement regulatory genes and hemolytic uremic syndromes	2008
Professor David Kavanagh	New roles for the major human 3′-5′ exonuclease TREX1 in human disease	2008
Professor David Kavanagh	Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations	2008
Professor David Kavanagh Dr Matthew Edey Dr Lisa Turnbull Professor Judith Goodship Dr Anne Lampe et al.	A non-synonymous polymorphism (arg240his) in C4b-binding protein is associated with atypical haemolytic uraemic syndrome and leads to impaired alternative pathway cofactor activity	2007
Professor David Kavanagh	C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy	2007
Professor David Kavanagh Dr Veronique Fremaux-Bacchi Professor Tim Goodship	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome	2007
Professor David Kavanagh	Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration	2007
Professor David Kavanagh Dr Veronique Fremaux-Bacchi Professor Tim Goodship	Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome	2007
Professor David Kavanagh Rachel Burgess Professor Judith Goodship Professor Tim Goodship	The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation	2007
Professor David Kavanagh Professor Tim Goodship	Update on evaluating complement in hemolytic uremic syndrome	2007
Professor David Kavanagh Professor Tim Goodship Dr Anna Richards	Atypical haemolytic uraemic syndrome	2006
Professor David Kavanagh Dr Anna Richards Rachel Burgess Professor Judith Goodship Professor Tim Goodship et al.	Does complement factor B have a role in the pathogenesis of atypical HUS?	2006
Professor David Kavanagh	Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications	2006
Dr Veronique Fremaux-Bacchi Professor David Kavanagh	Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome	2006
Professor David Kavanagh	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome	2006
Professor David Kavanagh Professor Tim Goodship	Membrane cofactor protein and factor I: Mutations and transplantation	2006
Emeritus Professor Geoffrey Toms Professor David Kavanagh	Acute respiratory infection in a renal transplant recipient	2005
Professor David Kavanagh	Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue	2005
Professor David Kavanagh Dr Liz Kemp Professor Judith Goodship Professor Tim Goodship	Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome	2005
Professor David Kavanagh	Risk factors for restless legs syndrome in dialysis patients	2005
Professor David Kavanagh	Peritoneal dialysis-associated peritonitis in Scotland (1999-2002)	2004
Professor David Kavanagh	Restless legs syndrome in patients on dialysis	2004
Professor David Kavanagh	The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation	2002
Professor David Kavanagh	Electrocardiogram and Outcome following Renal Transplantation	1999